Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMELY-PLEX
NCT07100990Phase 3Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jul 2025
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in optic neuritis (ON) and transverse myelitis (TM) (4 arms), sponsored by Mayo Clinic. Primary endpoints: High contrast visual acuity at 6 months and Expanded Disability Status Scale at 6 months. Started Jul 2025; status: recruiting.
02
Conditions
optic neuritis (ON)transverse myelitis (TM)
Beyond the preview
Go deeper on NCT07100990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100990.